The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions

The consensus Immunoscore has a prognostic value that has been confirmed in two randomized phase 3 clinical trials, and it provides a reliable estimate of the recurrence risk in colon cancer. The latest edition of the WHO classification of the Digestive System Tumors introduced for the first time th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagès, Franck, Taieb, Julien, Laurent-Puig, Pierre, Galon, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480815/
https://www.ncbi.nlm.nih.gov/pubmed/32939329
http://dx.doi.org/10.1080/2162402X.2020.1812221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480815/
https://www.ncbi.nlm.nih.gov/pubmed/32939329
http://dx.doi.org/10.1080/2162402X.2020.1812221

Ejemplares similares